Results 81 to 90 of about 2,131 (185)

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry

, 2023
Objective: this post hoc analysis aimed to evaluate the efficacy of fremanezumab in difficult-to-treat chronic migraine (CM) patients with and without psychiatric comorbidities (PCs), mainly anxiety and/or depression.
Emmanouil V. Dermitzakis, Panagiotis Soldatos, Dimitrios Rallis, Dimitrios Rikos, Michail Vikelis, Pantelis Litsardopoulos, Andreas A. Argyriou, Georgia Xiromerisiou   +7 more
core   +1 more source

Symptomatic Ferric Carboxymaltose‐Induced Hypophosphataemia: A Case Series of 11 Patients

eJHaem, Volume 7, Issue 4, August 2026.
Marina Weerheim, Heva Korevaar, Maurice Bizino, Gijs Fortrie, Loes Vrolijk, Ted Koster, Faiz Karim   +6 more
wiley   +1 more source

Fremanezumab for migraine [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine

, 2020
Objectives: Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, has demonstrated efficacy in adults with episodic or chronic migraine in clinical trials and has been ...
McAllister, P, Dotiwala, Z, Casciano, J, Thompson, S, Cohen, J, Lamerato, Lois, Krasenbaum, L   +6 more
core   +1 more source

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Neurology and Therapy
Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and  3 treatment failures and various comorbidities.
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group   +32 more
doaj   +1 more source

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study

Patient Preference and Adherence
Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly
Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M   +4 more
doaj  

Monthly versus quarterly Fremanezumab in real life: a comparison of effectiveness, tolerability, and adherence [PDF]

Background: While clinical trials have shown no differences between monthly and quarterly regimens of fremanezumab, limited real-life data exist for comparison. This study is aimed at comparing treatment regimens in real life.Methods: This observational,
Cano Sánchez, Luis Miguel, Campdelacreu i Fumadó, Jaume, Prat, Joan, Muñoz Vendrell, Albert, Huerta Villanueva, Mariano, Campoy Diaz, Sergio, García Sánchez, Sonia María   +6 more
core   +1 more source

Severe acute allergic reaction after switching anti-calcitonin gene-related peptide monoclonal antibodies: A case report

Cephalalgia Reports
Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are widely used for migraine prevention and are generally considered safe, with rare severe allergic reactions.
Ikko Wada, Atsushi Shima, Yuu Tatsuoka, Shintaro Toda, Mahito Yamada, Yasumasa Yamamoto   +5 more
doaj   +1 more source

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab

Cells
Calcitonin gene-related peptide (CGRP) and nitric oxide (NO) have been recognized as important mediators in migraine but their mechanisms of action and interaction have not been fully elucidated.
Nicola Benedicter, Birgit Vogler, Annette Kuhn, Jana Schramm, Kimberly D. Mackenzie, Jennifer Stratton, Mária Dux, Karl Messlinger   +7 more
doaj   +1 more source

Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

Cephalalgia Reports
Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM).
Hsiangkuo Yuan, Fred Cohen, Maurice T Driessen, Lynda J Krasenbaum, Mario Ortega, Mary Hopkins, Michael J Marmura   +6 more
doaj   +1 more source